Beyond Viral Suppression: Predictors of HBV Outcomes, Cure Potential, and HCC Risk
Nov
10
2025
Convention Center: Room 207, Level 2
5:00 PM
- 6:30 PM
Description
This session will explore how clinical and molecular markers can inform prognosis and therapeutic strategy in chronic hepatitis B. Presentations will compare the impact of current antiviral therapies on hepatocellular carcinoma (HCC) risk and examine how partial virologic responses and HBsAg decline correlate with long-term outcomes. The session will also address the evolving role of therapy discontinuation in HBeAg-negative patients, the utility of quantitative HBsAg and HBV RNA in distinguishing inactive carriers from those with partial cure, and the predictive value of biomarkers in selecting candidates for functional cure.Journey Maps
Presentations
5:00 PM
- 5:15 PM
Aug
06
2026
Convention Center - Room 207, Level 2
Similar Long-term Incidence of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B Patients Who Initiated Entecavir (ETV) versus Tenofovir Alafenamide (TAF): A REAL-B Study
Arpan Mohanty, MBBS, MSc
, Abstract Presenter
Hepatitis
Liver Cancer
5:30 PM
- 5:45 PM
Aug
06
2026
Convention Center - Room 207, Level 2
Outcomes Following Antiviral Therapy Discontinuation in HBeAg-Negative, Non-cirrhotic Chronic Hepatitis B Patients with Low Baseline HBsAg Titers: The ADAPT Trial
Arpan Mohanty, MBBS, MSc
, Abstract Presenter
Hepatitis
Liver Cancer
6:00 PM
- 6:15 PM
Aug
06
2026
Convention Center - Room 207, Level 2
Secretory ECM1a restores HBV-specific CD8⁺ T Cell response via integrin β1 blockade to promote HBsAg loss in chronic HBV infection
Arpan Mohanty, MBBS, MSc
, Abstract Presenter
Hepatitis
Liver Cancer
Objectives
- Compare the effects of different antiviral regimens on HCC risk and assess the prognostic implications of partial HBsAg decline
- Describe the clinical role of HBV RNA and quantitative HBsAg in distinguishing carriers, monitoring therapy, and evaluating cure potential
- Evaluate strategies such as treatment discontinuation in HBeAg-negative patients and the role of host immune remodeling in functional cure